Skip to main content

$0.018 -0.001 (-5.26%)

High

$0.02

Low

$0.02

Trades

52

Turnover

$20,686

Volume

1,123,417
30 June 2023 at 4:10pm
Register to track BNO and receive email alerts.
Subject
BNO Ann: Cleansing Notice - Concurrent Placement

BNO Ann: Appendix 2A - Concurrent Placement

BNO Ann: Appendix 2A - Entitlement Offer

BNO Ann: Change of Company Secretary

BNO Ann: Results of Entitlement Offer and Concurrent Placement

BNO Ann: Change of Company Secretary

BNO Ann: Proposed issue of Securities - BNO

BNO Ann: Concurrent Placement with Entitlement Offer to be Conducted

BNO Ann: Bionomics Completes Despatch of Entitlement Offer Booklet

BNO Ann: BNO at H.C. Wainwright Global Life Sciences Conference

BNO Ann: Proposed issue of Securities - BNO

BNO Ann: Entitlement Offer Notification to Option Holders

BNO Ann: Ineligible Shareholder letter

BNO Ann: Bionomics Ltd Entitlement Offer Booklet

BNO Ann: Cleansing Notice

BNO Ann: Bionomics Ltd Announces Non-Renounceable Entitlement Offer

BNO Ann: Change in substantial holding

BNO Ann: Change in substantial holding

BNO Ann: Appendix 2A

BNO Ann: Cleansing Notice

BNO Ann: Completion of Placement

BNO Ann: Half Yearly Report and Accounts

BNO Ann: Change in substantial holding

BNO Ann: Positive BNC210 PK Results for Solid Dose Formulation

BNO Ann: Bionomics and EmpathBio Joint Feasibility Assessment

BNO Ann: Notification of Change in Auditor

BNO Ann: Proposed issue of Securities - BNO

BNO Ann: $16 Million Capital Raise to Progress BNC210 PTSD Trial

BNO Ann: Response to ASX Price Query

BNO Ann: Appendix 4C - quarterly

BNO Ann: BNC105 / Nivolumab Treatment Completed in Phase 2 Trial

BNO Ann: Publication of Positive BNC210 Phase 2a Data in GAD Patients

BNO Ann: BNO Presenting at H.C. Wainwright BioConnect 2021 Conference

BNO Ann: BNO Initiates 7-Day Dosing Pharmacokinetic Study of BNC210

BNO Ann: Lapse of Employee Share Options & Warrants

BNO Ann: Appendix 3Y

BNO Ann: Final Director's Interest Notice

BNO Ann: Results of Meeting

BNO Ann: Executive Chairmans 2020 AGM Presentation

BNO Ann: Bionomics Licenses Drug Candidate BNC101 to Carina Biotech

BNO Ann: BNO Presenting at Neuropsychiatric Drug Development Summit

BNO Ann: Corporate Presentation November 2020

BNO Ann: Appendix 3Y

BNO Ann: Appendix 3Y

BNO Ann: Appendix 4C - quarterly

BNO Ann: Appendix 2A

BNO Ann: Bionomics Successfully Completes Retail Entitlement Offer

BNO Ann: Bionomics Annual Report 2020

BNO Ann: Appendix 4G / Corporate Governance Statement

BNO Ann: Notice of Annual General Meeting/Proxy Form

Register to track BNO and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX